LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

Home・Stock List・Puma Biotechnology Inc

Puma Biotechnology Inc

Closed

SectorHealthcare

6.99 -0.14

Buy Sell

Overview

Share price change

24h

Current

Min

6.98

Max

7.03

Key metrics
By Trading Economics
Income	-16M -3.8M
Sales	-31M 45M
P/E Sector Avg	14.833 49.888
EPS	-0.04
Profit margin	-8.375
Employees	179
EBITDA	-28M -1.3M

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	-28.88% downside

Dividends
By Dow Jones
Next Earnings	6 Aug 2026

Market Stats
By TradingEconomics
Market Cap	-21M 362M
Previous open	7.13
Previous close	6.99

News Sentiment

By Acuity

50%

155 / 344 Healthcare

Puma Biotechnology Inc Chart

Past performance is not a reliable indicator of future results.

Related News

5 Jun 2026, 19:20 UTC

Major Market Movers

Meta Platforms Slips on Report of Plans for Multibillion-Dollar Offering to Fund AI Buildout

5 Jun 2026, 21:27 UTC

Earnings

Carnage in Chip Stocks Hits Extra Hard in Top-Heavy Market -- WSJ

5 Jun 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

5 Jun 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

5 Jun 2026, 20:20 UTC

Acquisitions, Mergers, Takeovers

Altice France Group Had Granted Initial Exclusivity Period to Consortium Until May 15, Which Was Then Extended to June 5

5 Jun 2026, 20:19 UTC

Acquisitions, Mergers, Takeovers

Altice France Group, Bouygues Telecom, Free-iliad Group, Orange Exclusivity Period Extended by 48 Hours

5 Jun 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

5 Jun 2026, 19:26 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5 Jun 2026, 19:26 UTC

Market Talk

Hog Futures Tumble to Close Week -- Market Talk

5 Jun 2026, 19:10 UTC

Market Talk

Canada's GDP Targets From AI-Related Spending Require Second Look -- Market Talk

5 Jun 2026, 19:03 UTC

Market Talk

Oil Falls As Market Holds Out Hope for End to Conflict -- Market Talk

5 Jun 2026, 18:59 UTC

Market Talk

U.S. Natural-Gas Futures Pull Back After Gains -- Market Talk

5 Jun 2026, 18:47 UTC

Market Talk

Canada's Labor Market 'Retains Some Weakness' Despite Stellar May Report -- Market Talk

5 Jun 2026, 18:34 UTC

Market Talk

Hyperliquid ETFs Have Inflows Despite Crypto Weakness -- Market Talk

5 Jun 2026, 18:33 UTC

Acquisitions, Mergers, Takeovers

The U.S. Government Could Take a Stake in OpenAI. What That Means for Tech Stocks. -- Barrons.com

5 Jun 2026, 17:50 UTC

Earnings

Lululemon Slumps on Earnings. Bargain Hunters Beware. -- Barrons.com

5 Jun 2026, 17:27 UTC

Market Talk

U.S. Oil Rig Count Rises for 6th Straight Week -- Market Talk

5 Jun 2026, 16:48 UTC

Acquisitions, Mergers, Takeovers

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5 Jun 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

5 Jun 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

5 Jun 2026, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

5 Jun 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

5 Jun 2026, 15:44 UTC

Acquisitions, Mergers, Takeovers

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5 Jun 2026, 15:26 UTC

Market Talk

Gold Down Nearly 3% On Rate Hike Concerns After U.S. Hiring Data -- Market Talk

5 Jun 2026, 15:25 UTC

Earnings

Quantinuum Trades Below Offer Price. Why the Quantum Stock Is Sliding. -- Barrons.com

5 Jun 2026, 15:16 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5 Jun 2026, 15:16 UTC

Market Talk

Zcash Tumbles After Exploit Found -- Market Talk

5 Jun 2026, 15:09 UTC

Market Talk

Canada's May Jobs Report Underscores Volatility Worries Over Data Collection -- Market Talk

5 Jun 2026, 15:07 UTC

Market Talk

Canada's Economy Still Has Legs With Total Employment Close to Record -- Market Talk

5 Jun 2026, 15:05 UTC

Market Talk

Canada's Labor-Market Weakness to Start 2026 Likely 'Overstated' -- Market Talk

Peer Comparison

Price change

Puma Biotechnology Inc Forecast

Price Target

By TipRanks

-28.88% downside

12 Months Forecast

Average 5 USD -28.88%

High 5 USD

Low 5 USD

Based on 1 Wall Street analysts offering 12 month price targets forPuma Biotechnology Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

1 ratings

Buy

Hold

Sell

Based on 1 analysts giving stock ratings to Puma Biotechnology Inc - Dist in the past 3 months.

Sentiment

By Acuity

155 / 344 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.